

Macrophage Migration Inhibitory Factor Promotes Clearance of Pneumococcal Colonization

This information is current as of August 8, 2022.

Rituparna Das, Meredith I. LaRose, Christopher B. Hergott, Lin Leng, Richard Bucala and Jeffrey N. Weiser

J Immunol 2014; 193:764-772; Prepublished online 13 June 2014;

doi: 10.4049/jimmunol.1400133

<http://www.jimmunol.org/content/193/2/764>

References This article **cites 58 articles**, 23 of which you can access for free at:
<http://www.jimmunol.org/content/193/2/764.full#ref-list-1>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>

Macrophage Migration Inhibitory Factor Promotes Clearance of Pneumococcal Colonization

Rituparna Das,* Meredith I. LaRose,* Christopher B. Hergott,* Lin Leng,[†] Richard Bucala,[†] and Jeffrey N. Weiser*

Human genetic polymorphisms associated with decreased expression of macrophage migration inhibitory factor (MIF) have been linked to the risk of community-acquired pneumonia. Because *Streptococcus pneumoniae* is the leading cause of community-acquired pneumonia and nasal carriage is a precursor to invasive disease, we explored the role of MIF in the clearance of pneumococcal colonization in a mouse model. MIF-deficient mice (*Mif*^{-/-}) showed prolonged colonization with both avirulent (23F) and virulent (6A) pneumococcal serotypes compared with wild-type animals. Pneumococcal carriage led to both local upregulation of MIF expression and systemic increase of the cytokine. Delayed clearance in the *Mif*^{-/-} mice was correlated with reduced numbers of macrophages in upper respiratory tract lavages as well as impaired upregulation of MCP-1/CCL2. We found that primary human monocyte-derived macrophages as well as THP-1 macrophages produced MIF upon pneumococcal infection in a pneumolysin-dependent manner. Pneumolysin-induced MIF production required its pore-forming activity and phosphorylation of p38-MAPK in macrophages, with sustained p38-MAPK phosphorylation abrogated in the setting of MIF deficiency. Challenge with pneumolysin-deficient bacteria demonstrated reduced MIF upregulation, decreased numbers of macrophages in the nasopharynx, and less effective clearance. *Mif*^{-/-} mice also showed reduced Ab response to pneumococcal colonization and impaired ability to clear secondary carriage. Finally, local administration of MIF was able to restore bacterial clearance and macrophage accumulation in *Mif*^{-/-} mice. Our work suggests that MIF is important for innate and adaptive immunity to pneumococcal colonization and could be a contributing factor in genetic differences in pneumococcal disease susceptibility. *The Journal of Immunology*, 2014, 193: 764–772.

Despite the availability of vaccines and antimicrobial therapy, the burden of disease caused by *Streptococcus pneumoniae*, or the pneumococcus, remains significant worldwide. Among children < 5 y, there are 14 million cases of serious pneumococcal disease annually with ~1 million deaths, concentrated largely in developing nations (1). According to the Active Bacterial Core surveillance, 40,000 cases of invasive pneumococcal disease (meningitis, bacteremia, and bacteremic pneumonia) occurred in the United States in 2010 (2). In addition, the pneumococcus is estimated to be a contributing organism in 20–60% of cases of community-acquired pneumonia (CAP), which leads to ~600,000 annual hospitalizations, and is a leading cause of death among persons > 65 y (3).

Carriage of the pneumococcus in the nasopharynx is a risk factor for aspiration into the lungs and a well-established precursor to pneumonia and invasive disease with the colonizing serotype (4, 5). Pneumococcal carriage begins within the first 6 mo of life and sequential colonization is prevalent throughout childhood (6).

Immune mediators of colonization, their contribution to disease, and whether they can be assessed to understand disease risk and modulated in vaccination strategies are important areas for study. Cell-mediated immunity appears to be more important than humoral immunity in affecting primary pneumococcal clearance from the nasopharynx (7, 8). Evidence of the contribution the CD4 T cell response is suggested by the greater incidence of both pneumococcal colonization and disease among HIV-infected compared with uninfected subjects (9). In addition to Th1 immunity, animal as well as human studies have implicated the Th17 response in pneumococcal clearance (10, 11).

Although neutrophils are the first cell type to be recruited after colonization, the peak of their presence in the nasopharynx does not correlate with initiation of clearance, and their depletion does not seem to affect bacterial burden during carriage (8, 12, 13). Recently, a critical role for the sustained presence of macrophages in pneumococcal recognition and clearance, as well as coordination of the adaptive response, has been reported. Mice deficient in pattern recognition receptors show limited ability to generate local chemokine responses to enable recruitment and retention of macrophages in the upper airway and impaired pneumococcal clearance (11, 13, 14).

Defining the genetic determinants of immunity to pneumococcal disease risk is an area of active investigation. Some familial immune defects are known to confer profound risk for pneumococcal infection (15). However, the finding of increased susceptibility to pneumococcal disease in certain ethnic groups, despite controlling for disparities in socioeconomic status, suggests that there may be a broader genetic basis for susceptibility (16). Studies examining host genetics in both pneumococcal colonization and disease cohorts have proposed polymorphisms that may play a role, including a number affecting macrophage function (17, 18).

*Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104; and [†]Department of Medicine, Yale School of Medicine, New Haven, CT 06510

Received for publication January 16, 2014. Accepted for publication May 9, 2014.

This work was supported by National Institutes of Health Grants K08AI097223 (to R.D.), R01AI042310 and N01HHSN272201100019C (to R.B.), and R01AI38446 and R01AI05168 (to J.N.W.).

Address correspondence and reprint requests to Dr. Rituparna Das, University of Pennsylvania School of Medicine, 502 Johnson Pavilion, 36th Street and Hamilton Walk, Philadelphia, PA 19104. E-mail address: dasrit@mail.med.upenn.edu

Abbreviations used in this article: BMDM, bone marrow-derived macrophage; CAP, community-acquired pneumonia; MAPKi, MAPK inhibitor; MIF, migration inhibitory factor; rMIF, recombinant murine MIF; WT, wild-type.

Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14/\$16.00

Recently, an examination of host genetics in a cohort of 1700 older adults with CAP implicated two commonly occurring polymorphisms conferring increased expression of an innate mediator, macrophage migration inhibitory factor (MIF), in protection from disease (19). Microbiologic diagnosis is often challenging in CAP, but older age and community origin of the patients make the pneumococcus a likely pathogen in a majority of cases. The functional significance of these *MIF* variants, a tetranucleotide repeat in the promoter (−794 CATT) and a linked single nucleotide polymorphism (−173 G/C), in regulating macrophage response to various infectious and inflammatory stimuli has been demonstrated (20–23). Because pneumococcal carriage is a precursor to disease and macrophage responses are important in clearance, we chose to explore the role of MIF in a murine model of nasopharyngeal colonization.

MIF was the first cytokine discovered and named for its activity of retaining macrophages at the site of inflammation, making it an important factor to examine in pneumococcal colonization (24, 25). The expression of MIF by both immune cells (macrophages and lymphocytes) and epithelial cells (of the lung, gut, and skin) highlight its role in host–pathogen interaction (26, 27). MIF has been demonstrated to mediate recognition of Gram-negative bacteria and mycobacteria by regulating macrophage expression of molecular pattern recognition receptors (22, 28, 29). In addition, MIF promotes production of a variety of inflammatory cytokines by enabling nuclear translocation of NF- κ B and sustaining the activation of intracellular MAPKs (30–32). Studies with MIF-deficient (*Mif*^{−/−}) mice have shown that the role of MIF (detrimental versus beneficial) in different bacterial infections is dependent on the nature of the pathogen and the type of immunity induced. For instance, *Mif*^{−/−} mice are protected from overwhelming inflammation in LPS or superantigen-induced shock but are more susceptible to infection with *Salmonella typhimurium* and *Mycobacterium tuberculosis* (22, 33, 34).

Early studies attributed the accumulation of alveolar macrophages in rabbit models of pneumococcal pneumonia to the activity of MIF (35). Thereafter, the role of MIF in infections with Gram-positive pathogens, which do not produce a superantigen, such as the pneumococcus, has received less attention. In addition, the role of MIF in mucosal immunity or how it may mediate immune responses to the pneumococcus as a commensal as well as an agent of disease remains to be explored.

Materials and Methods

Mice

C57BL/6 (wild-type [WT]) mice were obtained from The Jackson Laboratory at 6–8 wk of age. *Mif*^{−/−} mice in the C57BL/6 background, backcrossed 10 generations, were obtained as described previously (22). WT and *Mif*^{−/−} mice were age and sex matched in all experiments. All procedures were performed in accordance with the Institutional Animal Care and Use Committee protocols at the University of Pennsylvania.

Bacterial strains and culture conditions

The P1121 strain of pneumococcus was used for nasal colonization experiments because it is a minimally passaged serotype 23F isolate obtained from the nasopharynx of a subject in a human carriage study (8). Another clinical isolate for serotype 6A also was used (36). 23F pneumococci as well as the previously described pneumolysin deletion (23F^{ply}[−]), point mutant (23F^{ply}^{W433F}), and revertant (23F^{ply}[−]→^{ply}⁺) strains also were used for macrophage infections where indicated (14). All bacteria were grown in tryptic soy broth (Life Technologies) at 37°C and 5% CO₂ until cultures reached midlog phase, OD₆₀₀ between 0.45 and 0.50.

Murine model of pneumococcal colonization

All bacterial strains were animal passaged prior to use in experiments and stored at −80°C in 20% glycerol. Inocula consisted of 10⁷ midlog-phase PBS-washed bacteria in 10 μ l PBS and were plated to confirm dose. They

were delivered to the nares of unanesthetized mice as described previously (37). At the indicated time points, mice were sacrificed, their trachea cannulated, and 200 μ l PBS was instilled. Lavage fluid was collected from the nares and serially diluted in PBS for plating on tryptic soy broth agar plates supplemented with catalase (Worthington Biochemicals). The lower limit of detection was either 100 or 20 CFU/ml lavage fluid, depending on the experiment. Blood was collected by cardiac puncture, and the serum was separated. Serum and lavages were assayed for murine MIF by specific ELISA. Serum was additionally assayed for antipneumococcal IgG as described previously (14).

Recombinant murine MIF (rMIF) was produced as previously described and ensured to be LPS free (38). PBS was used to dilute the rMIF to the indicated concentration. Because DMSO was present in the rMIF preparation, an identical amount of DMSO was added to PBS for the vehicle control treatment. Either rMIF or vehicle control was administered in a 10- μ l volume to the nares of unanesthetized mice for the frequency and duration described.

RNA extraction and RT-PCR

RNA was isolated from the upper respiratory tract following a lavage with 300 μ l RNA lysis buffer using an RNeasy Mini Kit (Qiagen), according to the manufacturer's protocol. cDNA was reverse transcribed using a high-capacity reverse transcription kit (Applied Biosystems). Approximately 25 ng cDNA was used as a template in reactions with 0.5 μ M of forward and reverse primers for MIF, GAPDH, and CCL2 and SYBR Green (Applied Biosystems), according to the manufacturer's protocol and as described previously (14, 22). Reactions were carried out using the StepOnePlus Real-Time PCR system, and quantitative comparisons were obtained using the $\Delta\Delta$ CT method (Applied Biosystems). Mock-infected WT mice were set as the reference to which relative comparisons were made.

Flow cytometry

The nasal lavages of five mice from each group were pooled, centrifuged to obtain a cell pellet, and resuspended in PBS with 1% BSA. Nonspecific binding was blocked using a rat anti-mouse Ab directed against the Fc γ III/IR (CD16/CD32) (BD Biosciences), and the cells were stained with the following rat anti-mouse cell surface Abs: Ly6G, Ly6C, CD11b, CD11c, Siglec-F, and F4/80 (BD Biosciences). All samples were fixed in 4% paraformaldehyde before analysis. Data were acquired using the FACSCalibur or LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star).

Macrophage culture and stimulation

Human macrophages were prepared from PBMCs isolated by Ficoll–Hypaque gradient centrifugation. The cells were resuspended in RPMI 1640 medium supplemented with 20% human serum (Gemini) and plated. After 2 h of culture, the adherent cells were washed extensively with PBS and cultured for 1 wk with human serum supplemented media to allow differentiation into monocyte-derived macrophages. THP-1 monocytes (American Type Culture Collection) were differentiated into macrophages by adding 50 ng/ml PMA (Sigma-Aldrich) to RPMI 1640 medium supplemented with 10% FCS culture medium for 16 h.

Both human monocyte derived macrophages and THP-1 cells were infected at a multiplicity of infection ratio of 10 bacteria/macrophage. The bacteria were spun onto the macrophages by centrifuging at 1500 \times g for 10 min. Invasion was allowed for 1 h at 37°C, 5%CO₂, then extracellular bacteria were washed away, and gentamicin-supplemented culture medium was added. Conditioned supernatants were collected at the indicated time points. Cell viability was confirmed by light microscopy and lactate dehydrogenase release assay (Roche). Macrophages were treated with the p38-MAPK inhibitor (MAPKi), SB203580 (Cell Signaling Technology), at a concentration of 10 μ M added to the culture media throughout the course of the experiment (or control DMSO supplemented culture medium) where indicated. Supernatants were assayed for human MIF by specific ELISA.

Bone marrow–derived macrophages (BMDMs) were prepared by differentiating cells flushed from the femur/tibiae of C57BL/6 mice of the appropriate genotype (WT or *Mif*^{−/−}) in the presence of supernatant from L929 cells as a source of M-CSF (in DMEM and 10% FCS) for 1 wk. The macrophages were harvested and replated for infection experiments. For BMDM experiments, infected macrophages were placed into the incubator immediately after centrifugation and lysed on ice with cold radioimmunoprecipitation assay buffer (Cell Signaling Technology) supplemented with protease inhibitor (Roche) and phosphatase inhibitor (Sigma-Aldrich), at the indicated time points.

Western blotting

Cell lysates were separated on a 10% polyacrylamide gel (Bio-Rad), and proteins were transferred to polyvinylidene difluoride membranes. Mem-

branes were probed first for phospho-p38-MAPK using a rabbit mAb (Cell Signaling Technology). The same membrane was then stripped and reprobed for total p38-MAPK (rabbit monoclonal; Cell Signaling Technology).

Statistics

Statistical comparisons were computed using the Mann-Whitney *U* test (nonparametric two-tailed *t* test) or one-way ANOVA as indicated in the figure legends (Prism 4; GraphPad Software). A *p* value < 0.05 was considered significant.

Results

Mif is required for the clearance of pneumococcal colonization from the nasopharynx

We found WT and *Mif*^{-/-} mice to be colonized to a similar degree after inoculation with 23F pneumococci, a clinically relevant serotype that is not associated with pneumonia or invasive disease in mice. By 7 d postchallenge, when bacterial clearance is initiated, a 2-fold higher bacterial load was noted in the nasopharynx of the *Mif*^{-/-} mice compared with their WT counterparts (Fig. 1A). In the WT animals, clearance progressed rapidly and was largely complete by 14 d. In contrast, the *Mif*^{-/-} mice had prolonged colonization through day 28 but were able to clear the infection by day 42 (data not shown). As expected, no symptoms of pneumococcal disease were observed in either group of animals.

To ensure that the clearance defect in *Mif*^{-/-} mice was not a phenomenon unique to serotype 23F pneumococci, we tested a serotype 6A isolate, which colonizes the murine nasopharynx and also causes bacteremia and sepsis. The *Mif*^{-/-} mice demonstrated almost a log higher bacterial load in their nasal washes at 7 d compared with their WT counterparts (Fig. 1B). Perhaps as a consequence of the greater bacterial burden, *Mif*^{-/-} animals also demonstrated greater mortality from sepsis compared with WT (54 versus 26%; *p* = 0.05).

Pneumococcal colonization leads to both local and systemic MIF expression

We next explored whether exposure to pneumococci in the nasopharynx could induce expression of MIF. At 3 d postcolonization, MIF expression in the nasopharynx was assayed by quantitative RT-PCR performed on RNA extracted from a nasal wash with lysis buffer. We found a basal level of MIF expression in the nasal wash (compared with *Mif*^{-/-} control; Fig. 2A). Upon pneumococcal colonization, the MIF expression was upregulated 2.5-fold. Our attempts to detect MIF protein in the nasopharynx were limited by dilution in the volume required for nasal lavage. Local exposure to

pneumococci in the nasal mucosa led to a rise in the circulating level of MIF at 3 d, without any evidence of bacterial dissemination (Fig. 2B). Notably, both local upregulation and systemic increase of MIF at 3 d preceded the onset of bacterial clearance, which began at 7 d and accelerated thereafter.

Cellular recruitment and chemokine expression are impaired in the absence of MIF

Macrophage recruitment to the nasopharynx has been demonstrated to effect pneumococcal clearance and to be dependent on bacterial recognition and local MCP-1 (CCL2) induction and signaling (11, 14). When we compared the cellular composition of nasal washes from WT and *Mif*^{-/-} mice over the course of pneumococcal colonization, we observed reduced numbers of macrophages (CD11b⁺, F4/80⁺ cells) in the *Mif*^{-/-} animals at both 3 and 7 d (Fig. 3A). Nasopharyngeal macrophages lacked expression of CD11c, Ly6C, Ly6G, and Siglec-F. The presence of macrophages in the nasopharynx of WT animals at 3 d correlated with transcriptional upregulation of MIF and preceded the initiation of pneumococcal clearance. The MIF-dependent defect in macrophage numbers was sustained thereafter and could be detected at 14 d postcolonization. The defect seemed to be specific to macrophages because neutrophil infiltration in the nasopharynx was unaffected in the absence of MIF (Fig. 3B).

We also found that *Mif*^{-/-} animals were impaired in their ability to induce transcription of MCP-1 (CCL2) in the nasopharynx during pneumococcal colonization (Fig. 3C). Although WT mice upregulated expression of the macrophage chemoattractant ~10-fold compared with uninfected, this was reduced ~60% in the *Mif*^{-/-} mice. Once again, dilution in the nasopharyngeal lavage precluded our ability to explore the differences in MCP-1 (CCL2) on the protein level.

Pneumolysin mediates the action of MIF in the nasopharynx

We next sought to examine the role of bacterial factors in mediating inflammatory macrophage responses in the nasopharynx. We focused on the pneumococcal pore-forming toxin, pneumolysin, which in addition to its role as a cytolysin has been demonstrated to be important for bacterial recognition by the innate immune system, subsequent initiation of the inflammatory cascade, and bacterial clearance (39–42). Sensing of pneumolysin has been proposed to occur through TLR4, NLRP3, as well as pore-formation and osmotic gradient-dependent mechanisms (43). When we compared the kinetics of pneumococcal clearance using pneumolysin sufficient and deficient pneumococci, we found that carriage was more dense and prolonged in the setting of pneumolysin deficiency in




FIGURE 1. MIF is important for the clearance of pneumococcal colonization. WT and MIF-deficient (*Mif*^{-/-}) mice were inoculated intranasally with 10⁷ CFU pneumococci. Lavages of the upper respiratory tract were performed thereafter to determine colonization density (colony-forming units per milliliter). WT mice (■) display accelerated clearance of 23F pneumococci compared with *Mif*^{-/-} mice (□, **A**). The MIF-dependent defect in colonization is evident using both 23F and 6A strains of pneumococci at 7 d (**B**). *n* ≥ 5 mice/experiment, at least two experiments. The dashed line indicates the limit of detection. Error bars represent SD, and horizontal lines indicate mean values. y-axis units depicting colony-forming units per milliliter are on a log-base 10 scale. **p* < 0.05, ***p* < 0.01, Mann-Whitney *U* test.




FIGURE 2. Pneumococcal colonization leads to local upregulation and systemic production of MIF in WT mice. Upper respiratory tract lavages were obtained 3 d after inoculation using RNA lysis buffer. RNA was isolated and reverse transcribed, and MIF expression level was measured by quantitative RT-PCR relative to GAPDH controls. Baseline MIF expression and MIF upregulation after colonization was noted in WT (A). Serum was obtained by cardiac puncture at 3 d postcolonization and analyzed for MIF by specific ELISA. Increased circulating MIF was noted in WT mice (B). Values are relative to mock-colonized WT mice \pm SD ($n \geq 10$ mice/group). * $p < 0.05$, ** $p < 0.01$, unpaired t test.

both the WT and *Mif*^{-/-} animals (Fig. 4A). However, the MIF-dependent defect in pneumococcal clearance was eliminated during colonization with pneumolysin-deficient pneumococci, suggesting that the role of MIF in pneumococcal clearance requires pneumolysin. We also found macrophage recruitment to the nasopharynx to be reduced and local upregulation of MIF to be impaired in the setting of colonization with pneumolysin-deficient pneumococci (23F^{ply-}; Fig. 4B, 4C).

Pneumolysin-stimulated phosphorylation of p38-MAPK is important for cytokine production and impaired in the absence of MIF


Bacterial infection is known to induce the production of MIF from a variety of cell types, and MIF has been proposed to modulate host-pathogen interactions by regulating macrophage expression of pattern recognition receptors such as TLR4 and dectin-1 (22, 28, 29). We first confirmed robust MIF production from human macrophages 4 h postinfection with pneumococci (Fig. 5A). Next, we examined the requirements of MIF production using a model of pneumococcal infection in human THP-1 monocytes differentiated into macrophages. Because pneumococci have been implicated in the lysis of host cells, we examined MIF production early

in the course of infection and confirmed cell viability to exclude death as a source of MIF.

We observed no induction of MIF postinfection of the cells with 23F^{ply-} bacteria compared with mock-infected controls, consistent with our findings on the role of pneumolysin in the nasopharynx. Genetic correction of the mutation, in the 23F^{ply-→ply+} strain, restored MIF production. We concluded that pneumolysin is required for pneumococcal-induced MIF production from macrophages.

To dissect the basis of the macrophage-pneumolysin interaction, we explored the role of TLR4 in this process. We hypothesized that if TLR4 is crucial for pneumolysin-dependent inflammatory cytokine production, reduced TLR4 in the *Mif*^{-/-} mice may underlie their abrogated response to pneumococcal colonization. To test this, we used a 23F^{plyW433F} mutant, which expresses a pneumolysin that can activate TLR4 but is deficient in its ability to form functional membrane pores. Osmotic stress from pneumolysin pores has been proposed to activate inflammation by an alternative mechanism—inducing phosphorylation of p38-MAPK (40, 43). Phosphorylation of MAPKs is known to be to an upstream event in the induction of a number of inflammatory cytokines. We found no MIF production from THP-1 macrophages

FIGURE 3. MIF is required for the macrophage influx and MCP-1 upregulation in response to pneumococcal colonization. Upper respiratory tract lavages were obtained 3 and 7 d after inoculation, and the composition of the cellular infiltrate was determined by flow cytometry. Numbers of macrophages (F4/80⁺,CD11b⁺, A) and neutrophils (Ly6G⁺,CD11b⁺, B) are shown in WT (gray bars) and *Mif*^{-/-} mice (white bars). Each bar represents the average number of events \pm SD in four experiments, each with five mice. MCP-1 upregulation in the WT mice was demonstrated by quantitative RT-PCR of RNA from nasal lavages and found to be reduced in the *Mif*^{-/-} mice (C). RT-PCR values are relative to mock-colonized WT mice \pm SD ($n \geq 10$ mice/group). * $p < 0.05$, ** $p < 0.01$, Mann-Whitney U test or unpaired t test.






FIGURE 4. Pneumolysin mediates the effect of MIF on pneumococcal colonization. Colonization experiments were performed in WT (■) and $Mif^{-/-}$ (□) mice using 10^7 CFU strain 23F and strain 23F^{ply-}. Nasal lavage was obtained at 14 d. 23F^{ply-} (pneumolysin-deficient) pneumococci colonized both WT and $Mif^{-/-}$ mice to a greater degree than 23F. The MIF-dependent defect in pneumococcal clearance was eliminated in the absence of pneumolysin (A). Macrophage influx, quantified by flow cytometry, was greater in WT mice colonized with strain 23F compared with 23F^{ply-} (B). MIF upregulation, assessed using quantitative RT-PCR of nasal lavage, was present in strain 23F colonization and absent in 23F^{ply-} colonization (C). Flow cytometry, mean \pm SD, $n = 5$ mice/experiment, four experiments. RT-PCR, relative to mock-colonized WT mice \pm SD, $n \geq 10$ mice/group. y-axis units depicting colony-forming units per milliliter are on a log-base 10 scale. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, Mann-Whitney U test or unpaired t test.

infected with the 23F^{plyW433F} pneumococci, suggesting that MIF's effects in pneumococci-induced inflammation are TLR4 independent and may be related to an alternate mechanism such as pore formation and p38-MAPK phosphorylation. To evaluate this, we treated macrophages with SB203580, a p38-MAPKi, and assayed MIF production. Because SB203580 inhibits all isoforms of p38-MAPKs, there is a potential for off-target effects with its use. We found MIF production to be diminished in the macrophages treated with the MAPKi compared with vehicle control-treated cells (Fig. 5B).

Phosphorylation of p38-MAPK is involved in the secretion of inflammatory cytokines from immune cells (43). Therefore, we next explored phosphorylation of p38-MAPK in WT and $Mif^{-/-}$ BMDMs after pneumococcal infection. Phospho-p38-MAPK was demonstrated immediately postinfection in the WT cells and sustained over the course of the experiment (Fig. 5C). By contrast, although some phospho-p38-MAPK was noted at early postinfection (2 min) in the $Mif^{-/-}$ cells, it was not observed thereafter (5 or 10 min). Interestingly, MAPK phosphatase 1, which has been postulated to be involved in the resolution of inflammatory responses, is observed to be downregulated by MIF and found to be constitutively active in the setting of MIF deficiency (44).

MIF is involved in the generation of the adaptive immune response to pneumococcal colonization


Given the important role of macrophages in coordinating the adaptive immune response, we next examined the role of MIF in generation of Ab responses to pneumococcal colonization and secondary bacterial clearance (14). After 6 wk of colonization, when WT and $Mif^{-/-}$ animals were clear of pneumococci in the nasopharynx, serum was obtained and analyzed for total anti-

pneumococcal IgG titers by ELISA. We found $Mif^{-/-}$ mice to have 10-fold lower Ab titers compared with their WT counterparts (Fig. 6A), despite more prolonged bacterial exposure. To evaluate the consequences of an impaired adaptive response, we reinoculated WT and $Mif^{-/-}$ mice with the colonizing inocula of 23F pneumococci 6 wk after primary challenge. Prior studies of secondary challenge in previously colonized WT mice demonstrated rapid pneumococcal clearance (11). We noted that $Mif^{-/-}$ mice remained colonized with $\sim 10^4$ pneumococci 5 d after secondary challenge compared with WT mice, which had $< 10^3$ bacteria recovered (Fig. 6B). These results demonstrate that the MIF-dependent macrophage effects during pneumococcal colonization also impact downstream adaptive immune responses.

Nasopharyngeal treatment with rMIF restores the MIF-dependent defects in pneumococcal clearance

Finally, we sought to rescue MIF effects on pneumococcal clearance by replacing the cytokine in $Mif^{-/-}$ mice. $Mif^{-/-}$ mice were dosed with 100 ng rMIF or vehicle control in the nasopharynx every other day after pneumococcal inoculation for a period of 2 wk. The rMIF-treated mice had a 1.5 log reduction in their nasopharyngeal bacterial load compared with vehicle control-treated animals (Fig. 7A). We also evaluated the cellular composition of the nasopharyngeal lavage from the $Mif^{-/-}$ animals with and without MIF treatment. We found MIF administration to be associated with an accumulation of macrophages to a level similar to that observed in WT animals (Fig. 7B). Taken together, the results of our MIF replacement experiments confirm that the presence of MIF in the nasopharynx has a direct effect on the recruitment and retention of macrophages, which enables them to promote pneumococcal clearance.

FIGURE 5. Human macrophages differentiated from PBMCs were infected with 23F pneumococci at a multiplicity of infection of 10:1, and their culture supernatant was assayed for MIF production by specific ELISA (**A**). THP-1 macrophages, differentiated by PMA, were infected with the indicated strain of pneumococci. MIF production postinfection was diminished in the 23F^{ply⁻} and 23F^{ply^{W433F}} strains compared with 23F and restored in the revertant 23F^{ply⁻→ply⁺} strain (**B**). MIF production was abrogated by inhibition of p38-MAPK phosphorylation by treatment with SB203580 (a specific MAPKi, **C**). Phosphorylation of p38-MAPK was observed by Western blotting postinfection of cultured BMDMs from WT mice with 23F pneumococci and quantified by densitometry. p38-MAPK phosphorylation was diminished in BMDMs of *Mif*^{-/-} mice (**D**). Mean ± SD values depicted from four independent experiments. Representative Western blot shown and densitometry performed from four independent experiments. **p* < 0.05, ***p* < 0.01, ****p* < 0.001, one-way ANOVA.



Discussion

We show in this study that MIF is expressed by macrophages upon pneumococcal infection in a pneumolysin-dependent manner, via a mechanism that requires the phosphorylation of p38-MAPK. In addition, we demonstrate that MIF promotes the MCP-1 (CCL2)-mediated recruitment and retention of macrophages in the nasopharynx to allow for clearance of primary carriage and also is required for the generation of adaptive responses—Ab production and clearance after repeat pneumococcal challenge. Taken together with our finding that administration of rMIF to the MIF-deficient animals recovers these defects, our studies indicate that

MIF is both necessary and sufficient for the accumulation of macrophages in the nasopharynx and subsequent pneumococcal clearance.

Our work in the mouse model suggests that a setting of relative MIF deficiency may be associated with inability to clear pneumococcal carriage. Although it was not possible to demonstrate a correlation between higher nasal colonization and pneumonia in the animal model using the 23F serotype, clinical data correlating colonization burden to pneumonia suggest that in humans, relative MIF deficiency may confer a propensity for downstream disease. These results are in support of the clinical findings reported by Yende et al. (19) reporting older adults with the low-expresser *MIF*




FIGURE 6. MIF promotes the generation of adaptive responses to pneumococcal colonization. Mice were inoculated intranasally with 10⁷ CFU 23F pneumococci and, 21 d after inoculation, were sacrificed, serum was isolated, and levels of antipneumococcal serum IgG was determined by ELISA. Values are expressed as geometric mean titers. WT mice (■) had circulating higher Ab titers to pneumococcus compared with *Mif*^{-/-} mice (□, **A**). Mice were allowed to clear primary colonization for 6 wk and then rechallenged with 10⁷ CFU 23F pneumococci. Nasal lavage was obtained at 5 d. *Mif*^{-/-} mice had higher levels of colonization compared with WT (**B**). *n* ≥ 5 mice/experiment, at least two experiments. y-axis units depicting colony-forming units per milliliter are on a log-base 10 scale. ***p* < 0.01, Mann-Whitney *U* test.




FIGURE 7. Nasopharyngeal treatment with rMIF recovers the MIF-dependent defect in macrophage recruitment and pneumococcal clearance. *Mif*^{-/-} mice were colonized with 10⁷ 23F pneumococci and treated every other day with either 100 ng rMIF in PBS or vehicle control. Nasal lavage was obtained at 14 d. MIF treatment led to greater clearance of pneumococcal colonization compared with control (A). Macrophage influx, quantified by flow cytometry, was also greater in the rMIF treated mice compared with vehicle treated controls (B). Horizontal lines indicate mean values, and dashed line is the limit of detection. Flow cytometry, mean ± SD, *n* = 5 mice/experiment, three experiments. *y*-axis units depicting CFU/ml are on a log-base 10 scale. **p* < 0.05, ***p* < 0.01, Mann–Whitney *U* test.

genotype to be more likely to develop CAP as well as suffer adverse outcomes. The functionality of human *MIF* polymorphisms in the response to infectious stimuli has been demonstrated in Gram-negative bacterial infection as well as in tuberculous and meningococcal disease (21–23). One study also has suggested that MIF mRNA upregulation in PBMCs upon pneumococcal infection is influenced by *MIF* genotype (45). Further investigation is necessary to analyze the *MIF*-genotype effect on nasopharyngeal and systemic pneumococcal responses. In addition, genetic examinations of dedicated patient cohorts will be required to ascertain the impact of immune factor polymorphisms on the risk for pneumococcal colonization and disease. Reduced ability to clear primary colonization or develop adequate adaptive responses to deal with subsequent challenge, both of which were affected by MIF in our model, are risk factors for pneumococcal disease in children and adults (46).

Genetic examinations thus far suggest a dual role for MIF in infection with Gram-negative pathogens—promoting pathogen elimination in some scenarios but causing inflammatory damage in others. In meningococcal disease, the low-expressor *MIF* genotype is associated with mortality from disease but protective from its occurrence (23). High expression of *MIF* is correlated with morbidity and mortality in sepsis but protects older adults from developing Gram-negative bacteremia (21, 47). In lower respiratory tract infection with *Pseudomonas aeruginosa*, the absence of MIF-protected mice from neutrophil-dependent inflammatory pathology and genetic low expressors of MIF among individuals with cystic fibrosis were protected from *Pseudomonas* pneumonia (48, 49). Fewer studies have examined the role of MIF in the response to Gram-positive pathogens, and work is under way to determine whether MIF is beneficial or detrimental in host responses to pneumococcal infection in the lower respiratory tract. A preliminary genetic examination of patients with pneumococcal disease found meningitis to be associated with high-expression *MIF* genotypes, suggesting that MIF may play divergent roles depending on the anatomic site of host–pneumococcal interaction and whether the inflammatory response is beneficial or detrimental to the host (50).

MIF appears to be critical for the control of infections where recruitment and retention of macrophages plays a central role in mounting an effective immune response. The source of the macrophages in the nasopharynx is an active area of investigation. Studies to date have implicated embryologically divergent origins for the circulating monocytes and alveolar macrophages in the lung; whether there are analogous populations of cells in the nasopharynx is unknown (51). The absence of CD11b on both al-

veolar and nasopharyngeal macrophages suggests phenotypic similarities, but the relatively small number of cells in the latter group make their immunologic characterization challenging. MIF may play a role in the migration of circulating monocytes into tissues in an MCP-1 (CCL2)–dependent manner, setting up a positive-feedback loop as more cells are recruited (52). In addition, some of the seminal studies of MIF described its ability to inhibit migration and promote retention of alveolar macrophages (35). Recruitment of circulating monocytes or retention of tissue macrophages may serve as the mechanism by which MIF promotes nasopharyngeal macrophage accumulation in pneumococcal colonization. We found no MIF-dependent defects in uptake or killing of pneumococci in vitro by BMDMs (data not shown), leading us to the conclusion that it is MIF's role in the recruitment/retention of macrophages in the nasopharynx that underlie its importance in clearance of colonization.

This study also highlights the immunomodulatory properties of pneumolysin, which serves as a virulence factor for in invasive pneumococcal disease, but has been found to promote bacterial clearance from the nasopharynx (39, 53). We report that TLR4-independent stimulation of macrophages to effect inflammatory cytokine production requires phosphorylation of p38-MAPK, a process which had been previously reported in epithelial cells, both in vitro and in vivo (43, 54). The action of a bacterial cytolysin to promote pattern recognition receptor–independent cytokine production in innate immune cells has been described with the β-hemolysin of another Gram-positive pathogen—group B *Streptococcus* (55). A potential mechanism for MAPK-dependent secretion of MIF may be through the binding of the transcription factor, specificity protein 1, to the MIF promoter (56).

Investigating host and bacterial factors that affect immunity in the nasal mucosa contributes to the understanding of how the pneumococcus is able to exist as a commensal in the upper airways but cause invasive disease in the lower tract (57). Although the role of MIF in pulmonary immune responses has been examined, this work is the first examination of its function in the upper airways, to our knowledge. MIF production has been observed in human gastric and intestinal mucosa upon Gram-negative bacterial infection (58, 59). We demonstrate a role for MIF in development of respiratory mucosal immunity—macrophage retention and chemokine production—required for pneumococcal clearance. We focused on MIF production from macrophages in the pneumococcal response, but further studies are necessary to determine whether there are additional cellular sources (e.g., dendritic cells or epithelial cells). Finally, our work adds pneumolysin-mediated phosphorylation of p38-MAPK to pattern recognition receptor activation

as a mechanism of macrophage activation in response to pneumococcal challenge. Further investigations of the role of MIF in mucosal immunity will be important to the understanding local protective responses in response to vaccination as well as the contribution of host genetics to the risk of pneumococcal disease.

Disclosures

The authors have no financial conflicts of interest.

References

- O'Brien, K. L., L. J. Wolfson, J. P. Watt, E. Henkle, M. Deloria-Knoll, N. McCall, E. Lee, K. Mulholland, O. S. Levine, and T. Cherian. 2009. Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates. *Lancet* 374: 893–902.
- Centers for Disease Control and Prevention. 2010. Active Bacterial Core Surveillance (ABCs) Report—Emerging Infections Program Network: *Streptococcus pneumoniae*. Centers for Disease Control and Prevention, Atlanta, GA.
- Jackson, L. A., K. M. Neuzil, O. Yu, P. Benson, W. E. Barlow, A. L. Adams, C. A. Hanson, L. D. Mahoney, D. K. Shay, and W. W. Thompson. 2003. Effectiveness of pneumococcal polysaccharide vaccine in older adults. *N. Engl. J. Med.* 348: 1747–1755.
- Bogaert, D., R. De Groot, and P. W. Hermans. 2004. *Streptococcus pneumoniae* colonisation: the key to pneumococcal disease. *Lancet Infect. Dis.* 4: 144–154.
- Albrich, W. C., S. A. Madhi, P. V. Adrian, N. van Niekerk, T. Mareletsi, C. Cutland, M. Wong, M. Khoosal, A. Karstaedt, P. Zhao, et al. 2012. Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia. *Clin. Infect. Dis.* 54: 601–609.
- Gray, B. M., G. M. Converse, III, and H. C. Dillon, Jr. 1980. Epidemiologic studies of *Streptococcus pneumoniae* in infants: acquisition, carriage, and infection during the first 24 months of life. *J. Infect. Dis.* 142: 923–933.
- McCool, T. L., T. R. Cate, G. Moy, and J. N. Weiser. 2002. The immune response to pneumococcal proteins during experimental human carriage. *J. Exp. Med.* 195: 359–365.
- McCool, T. L., and J. N. Weiser. 2004. Limited role of antibody in clearance of *Streptococcus pneumoniae* in a murine model of colonization. *Infect. Immun.* 72: 5807–5813.
- Madhi, S. A., P. Adrian, L. Kuwanda, C. Cutland, W. C. Albrich, and K. P. Klugman. 2007. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by *Streptococcus pneumoniae*—and associated interactions with *Staphylococcus aureus* and *Haemophilus influenzae* colonization—in HIV-infected and HIV-uninfected children. *J. Infect. Dis.* 196: 1662–1666.
- Lu, Y. J., J. Gross, D. Bogaert, A. Finn, L. Bagrade, Q. Zhang, J. K. Kolls, A. Srivastava, A. Lundgren, S. Forte, et al. 2008. Interleukin-17A mediates acquired immunity to pneumococcal colonization. *PLoS Pathog.* 4: e1000159.
- Zhang, Z., T. B. Clarke, and J. N. Weiser. 2009. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. *J. Clin. Invest.* 119: 1899–1909.
- Nelson, A. L., A. M. Roche, J. M. Gould, K. Chim, A. J. Ratner, and J. N. Weiser. 2007. Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. *Infect. Immun.* 75: 83–90.
- Matthias, K. A., A. M. Roche, A. J. Standish, M. Shchepetov, and J. N. Weiser. 2008. Neutrophil-toxin interactions promote antigen delivery and mucosal clearance of *Streptococcus pneumoniae*. *J. Immunol.* 180: 6246–6254.
- Davis, K. M., S. Nakamura, and J. N. Weiser. 2011. Nod2 sensing of lysozyme-digested peptidoglycan promotes macrophage recruitment and clearance of *S. pneumoniae* colonization in mice. *J. Clin. Invest.* 121: 3666–3676.
- Picard, C., A. Puel, J. Bustamante, C. L. Ku, and J. L. Casanova. 2003. Primary immunodeficiencies associated with pneumococcal disease. *Curr. Opin. Allergy Clin. Immunol.* 3: 451–459.
- Burton, D. C., B. Flannery, N. M. Bennett, M. M. Farley, K. Gershman, L. H. Harrison, R. Lynfield, S. Petit, A. L. Reingold, W. Schaffner, et al. 2010. Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults. *Am. J. Public Health* 100: 1904–1911.
- Brouwer, M. C., J. de Gans, S. G. Heckenberg, A. H. Zwinderman, T. van der Poll, and D. van de Beek. 2009. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. *Lancet Infect. Dis.* 9: 31–44.
- Vuononvirta, J., L. Toivonen, K. Gröndahl-Yli-Hannuksela, A. M. Barkoff, L. Lindholm, J. Mertsola, V. Peltola, and Q. He. 2011. Nasopharyngeal bacterial colonization and gene polymorphisms of mannose-binding lectin and Toll-like receptors 2 and 4 in infants. *PLoS One* 6: e26198.
- Yende, S., D. C. Angus, L. Kong, J. A. Kellum, L. Weissfeld, R. Ferrell, D. Finegold, M. Carter, L. Leng, Z. Y. Peng, and R. Bucala. 2009. The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. *FASEB J.* 23: 2403–2411.
- Sreih, A., R. Ezzeddine, L. Leng, A. LaChance, G. Yu, Y. Mizue, L. Subrahmanyam, B. A. Pons-Estel, A. K. Abelson, I. Gunnarsson, et al. 2011. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. *Arthritis Rheum.* 63: 3942–3951.
- Das, R., L. Subrahmanyam, I. V. Yang, D. van Duin, R. Levy, M. Piecychna, L. Leng, R. R. Montgomery, A. Shaw, D. A. Schwartz, and R. Bucala. 2014. Functional polymorphisms in the gene encoding macrophage migration inhibitory factor are associated with Gram-negative bacteremia in older adults. *J. Infect. Dis.* 209: 764–768.
- Das, R., M. S. Koo, B. H. Kim, S. T. Jacob, S. Subbian, J. Yao, L. Leng, R. Levy, C. Murchison, W. J. Burman, et al. 2013. Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. USA* 110: E2997–E3006.
- Renner, P., T. Roger, P. Y. Bochud, T. Sprong, F. C. Sweep, M. Bochud, S. N. Faust, E. Haralambous, H. Betts, A. L. Chanson, et al. 2012. A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. *FASEB J.* 26: 907–916.
- David, J. R. 1966. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. *Proc. Natl. Acad. Sci. USA* 56: 72–77.
- Bloom, B. R., and B. Bennett. 1966. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. *Science* 153: 80–82.
- Calandra, T., J. Bernhagen, R. A. Mitchell, and R. Bucala. 1994. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. *J. Exp. Med.* 179: 1895–1902.
- Bacher, M., A. Meinhardt, H. Y. Lan, W. Mu, C. N. Metz, J. A. Chesney, T. Calandra, D. Gerns, T. Donnelly, R. C. Atkins, and R. Bucala. 1997. Migration inhibitory factor expression in experimentally induced endotoxemia. *Am. J. Pathol.* 150: 235–246.
- Roger, T., J. David, M. P. Glauser, and T. Calandra. 2001. MIF regulates innate immune responses through modulation of Toll-like receptor 4. *Nature* 414: 920–924.
- Roger, T., J. Delaloye, A. L. Chanson, M. Giddey, D. Le Roy, and T. Calandra. 2013. Macrophage migration inhibitory factor deficiency is associated with impaired killing of Gram-negative bacteria by macrophages and increased susceptibility to *Klebsiella pneumoniae* sepsis. *J. Infect. Dis.* 207: 331–339.
- Mitchell, R. A., C. N. Metz, T. Peng, and R. Bucala. 1999. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF): regulatory role in cell proliferation and glucocorticoid action. *J. Biol. Chem.* 274: 18100–18106.
- Daun, J. M., and J. G. Cannon. 2000. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic I κ B α . *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 279: R1043–R1049.
- Mitchell, R. A., H. Liao, J. Chesney, G. Fingerle-Rowson, J. Baugh, J. David, and R. Bucala. 2002. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. *Proc. Natl. Acad. Sci. USA* 99: 345–350.
- Koebnick, H., L. Grode, J. R. David, W. Rohde, M. S. Rolph, H. W. Mittrücker, and S. H. Kaufmann. 2002. Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against *Salmonella typhimurium*. *Proc. Natl. Acad. Sci. USA* 99: 13681–13686.
- Calandra, T., L. A. Spiegel, C. N. Metz, and R. Bucala. 1998. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. *Proc. Natl. Acad. Sci. USA* 95: 11383–11388.
- Cantey, J. R., and W. L. Hand. 1974. Cell-mediated immunity after bacterial infection of the lower respiratory tract. *J. Clin. Invest.* 54: 1125–1134.
- Roche, A. M., S. J. King, and J. N. Weiser. 2007. Live attenuated *Streptococcus pneumoniae* strains induce serotype-independent mucosal and systemic protection in mice. *Infect. Immun.* 75: 2469–2475.
- Wu, H. Y., A. Virolainen, B. Mathews, J. King, M. W. Russell, and D. E. Briles. 1997. Establishment of a *Streptococcus pneumoniae* nasopharyngeal colonization model in adult mice. *Microb. Pathog.* 23: 127–137.
- Bernhagen, J., R. A. Mitchell, T. Calandra, W. Voelter, A. Cerami, and R. Bucala. 1994. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). *Biochemistry* 33: 14144–14155.
- van Rossum, A. M., E. S. Lysenko, and J. N. Weiser. 2005. Host and bacterial factors contributing to the clearance of colonization by *Streptococcus pneumoniae* in a murine model. *Infect. Immun.* 73: 7718–7726.
- Malley, R., P. Henneke, S. C. Morse, M. J. Cieslewicz, M. Lipsitch, C. M. Thompson, E. Kurt-Jones, J. C. Paton, M. R. Wessels, and D. T. Golenbock. 2003. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. *Proc. Natl. Acad. Sci. USA* 100: 1966–1971.
- McNeela, E. A., A. Burke, D. R. Neill, C. Baxter, V. E. Fernandes, D. Ferreira, S. Smeaton, R. El-Rachkidy, R. M. McLoughlin, A. Mori, et al. 2010. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. *PLoS Pathog.* 6: e1001191.
- Witzenrath, M., F. Pache, D. Lorenz, U. Koppe, B. Gutber, C. Tabeling, K. Reppe, K. Meixenberger, A. Dorhoi, J. Ma, et al. 2011. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. *J. Immunol.* 187: 434–440.
- Ratner, A. J., K. R. Hippe, J. L. Aguilar, M. H. Bender, A. L. Nelson, and J. N. Weiser. 2006. Epithelial cells are sensitive detectors of bacterial pore-forming toxins. *J. Biol. Chem.* 281: 12994–12998.
- Aeberli, D., Y. Yang, A. Mansell, L. Santos, M. Leech, and E. F. Morand. 2006. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. *FEBS Lett.* 580: 974–981.
- Temple, S. E., K. Y. Cheong, P. Price, and G. W. Waterer. 2008. The microsatellite, macrophage migration inhibitory factor -794, may influence gene expression in human mononuclear cells stimulated with *E. coli* or *S. pneumoniae*. *Int. J. Immunogenet.* 35: 309–316.

46. Ferreira, D. M., D. R. Neill, M. Bangert, J. F. Gritzfeld, N. Green, A. K. Wright, S. H. Pennington, L. Bricio-Moreno, A. T. Moreno, E. N. Miyaji, et al. 2013. Controlled human infection and rechallenge with *Streptococcus pneumoniae* reveals the protective efficacy of carriage in healthy adults. *Am. J. Respir. Crit. Care Med.* 187: 855–864.
47. Lehmann, L. E., M. Book, W. Hartmann, S. U. Weber, J. C. Schewe, S. Klaschik, A. Hoefft, and F. Stüber. 2009. A MIF haplotype is associated with the outcome of patients with severe sepsis: a case control study. *J. Transl. Med.* 7: 100.
48. Bozza, M., A. R. Satoskar, G. Lin, B. Lu, A. A. Humbles, C. Gerard, and J. R. David. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. *J. Exp. Med.* 189: 341–346.
49. Plant, B. J., C. G. Gallagher, R. Bucala, J. A. Baugh, S. Chappell, L. Morgan, C. M. O'Connor, K. Morgan, and S. C. Donnelly. 2005. Cystic fibrosis, disease severity, and a macrophage migration inhibitory factor polymorphism. *Am. J. Respir. Crit. Care Med.* 172: 1412–1415.
50. Doernberg, S., B. Schaaf, K. Dalhoff, L. Leng, A. Beitin, V. Quagliarello, and R. Bucala. 2011. Association of macrophage migration inhibitory factor (MIF) polymorphisms with risk of meningitis from *Streptococcus pneumoniae*. *Cytokine* 53: 292–294.
51. Williams, M., I. De Kleer, S. Henri, S. Post, L. Vanhoutte, S. De Prijck, K. Deswarte, B. Malissen, H. Hammad, and B. N. Lambrecht. 2013. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. *J. Exp. Med.* 210: 1977–1992.
52. Gregory, J. L., E. F. Morand, S. J. McKeown, J. A. Ralph, P. Hall, Y. H. Yang, S. R. McColl, and M. J. Hickey. 2006. Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. *J. Immunol.* 177: 8072–8079.
53. Berry, A. M., J. Yother, D. E. Briles, D. Hansman, and J. C. Paton. 1989. Reduced virulence of a defined pneumolysin-negative mutant of *Streptococcus pneumoniae*. *Infect. Immun.* 57: 2037–2042.
54. Beisswenger, C., C. B. Coyne, M. Shchepetov, and J. N. Weiser. 2007. Role of p38 MAP kinase and transforming growth factor- β signaling in trans-epithelial migration of invasive bacterial pathogens. *J. Biol. Chem.* 282: 28700–28708.
55. Bebien, M., M. E. Hensler, S. Davanture, L. C. Hsu, M. Karin, J. M. Park, L. Alexopoulou, G. Y. Liu, V. Nizet, and T. Lawrence. 2012. The pore-forming toxin β hemolysin/cytolysin triggers p38 MAPK-dependent IL-10 production in macrophages and inhibits innate immunity. *PLoS Pathog.* 8: e1002812.
56. Roger, T., X. Ding, A. L. Chanson, P. Renner, and T. Calandra. 2007. Regulation of constitutive and microbial pathogen-induced human macrophage migration inhibitory factor (MIF) gene expression. *Eur. J. Immunol.* 37: 3509–3521.
57. Weiser, J. N. 2010. The pneumococcus: why a commensal misbehaves. *J. Mol. Med.* 88: 97–102.
58. Maaser, C., L. Eckmann, G. Paesold, H. S. Kim, and M. F. Kagnoff. 2002. Ubiquitous production of macrophage migration inhibitory factor by human gastric and intestinal epithelium. *Gastroenterology* 122: 667–680.
59. Fehlings, M., L. Drobbe, V. Moos, P. Renner Viveros, J. Hagen, M. Beigier-Bompadre, E. Pang, E. Belogolova, Y. Churin, T. Schneider, et al. 2012. Comparative analysis of the interaction of *Helicobacter pylori* with human dendritic cells, macrophages, and monocytes. *Infect. Immun.* 80: 2724–2734.